Table 1.
Clinical characteristics of the studied population in total and stratified by age groups.
| All patients | ≥75–<80 | ≥80–<90 | ≥90 | |
|---|---|---|---|---|
| n | 2943 | 1033 | 1464 | 446 |
| Age (y) | 82 (78–87) | 77 (75–78) | 84 (82–87) | 92 (91–94) |
| Female gender | 1718 (58.4) | 524 (50.7) | 865 (59.1) | 329 (73.8) |
| BMI | 24.5 (21.9–27.6) | 25.7 (23.0–29.0) | 24.2 (21.8–27.1) | 22.8 (20.3–25.1) |
| Underweight | 137 (4.7) | 26 (2.6) | 66 (4.6) | 45 (10.3) |
| Normal weight | 1460 (50.6) | 425 (41.9) | 762 (53.0) | 273 (62.8) |
| Overweight | 895 (31.0) | 367 (36.2) | 439 (30.5) | 89 (20.5) |
| Obese | 396 (13.7) | 196 (19.3) | 172 (12.0) | 28 (6.4) |
| New onset AF/AFL | 1402 (47.6) | 476 (46.1) | 711 (48.6) | 215 (48.2) |
| Prevalent CV disease | ||||
| IS/TIA/SE | 563 (19.1) | 157 (15.2) | 297 (20.3) | 109 (24.4) |
| Myocardial infarction | 414 (14.1) | 109 (10.6) | 220 (15.0) | 85 (19.1) |
| Other vascular disease | 484 (16.5) | 153 (14.8) | 257 (17.6) | 74 (16.6) |
| Heart failure | 962 (32.7) | 248 (24.0) | 506 (34.6) | 208 (46.6) |
| Previous bleeding | 430 (14.6) | 124 (12.0) | 216 (14.8) | 90 (20.2) |
| Prevalent CV risk factors | ||||
| Diabetes mellitus | 453 (15.4) | 173 (16.8) | 239 (16.3) | 41 (9.2) |
| Hypertension | 1962 (66.7) | 694 (67.2) | 969 (66.2) | 299 (67.0) |
| Lipidlowering treatment | 712 (24.2) | 292 (28.3) | 352 (24.0) | 68 (15.3) |
| Renal function | ||||
| absolute eGFR (ml/min) | 52.1 (36.6–70.9) | 67.8 (53.4–86.7) | 48.3 (36.2–63.6) | 31.2 (24.3–42.2) |
| ≥60 | 1087 (37.9) | 643 (64.4) | 419 (29.3) | 25 (5.8) |
| 45–59 | 661 (23.1) | 214 (21.4) | 387 (27.0) | 60 (13.8) |
| 30–44 | 687 (24.0) | 108 (10.8) | 430 (30.1) | 149 (34.3) |
| 15–29 | 379 (13.2) | 26 (2.6) | 175 (12.2) | 178 (40.9) |
| <15 | 51 (1.8) | 8 (0.8) | 20 (1.4) | 23 (5.3) |
| Antithrombotic treatment at discharge | ||||
| Warfarin | 1377 (46.8) | 553 (53.5) | 695 (47.5) | 129 (28.9) |
| DOAC | 810 (27.5) | 313 (30.3) | 397 (27.1) | 100 (22.4) |
| ASA | 461 (15.7) | 93 (9.0) | 236 (16.1) | 132 (29.6) |
| None | 157 (5.3) | 37 (3.6) | 70 (4.8) | 50 (11.2) |
| TTR* | 0.67 (0.53–0.78) | 0.70 (0.57–0.80) | 0.65 (0.50–0.75) | 0.62 (0.50–0.71) |
| Risk scores | ||||
| CHA2DS2 VASc | 4 (3–5) | 4 (3–5) | 4 (3–5) | 4 (4–5) |
| 2–4 | 1720 (58.4) | 724 (70.1) | 928 (63.4) | 273 (61.2) |
| ≥5 | 1018 (34.6) | 309 (29.9) | 536 (36.6) | 173 (38.8) |
| HAS-BLED | 2 (2–3) | 2 (2–3) | 2 (2–3) | 2 (2–3) |
| <2 | 571 (19.4) | 203 (19.7) | 280 (19.1) | 88 (19.7) |
| 2 | 1359 (46.2) | 495 (47.9) | 679 (46.4) | 185 (41.5) |
| ≥3 | 1013 (34.4) | 335 (32.4) | 505 (34.5) | 173 (38.8) |
Continuous variables are reported as median (interquartile range), categorical variables as number (percentage).
Abbreviations: Y: years; BMI: body mass index; AF: atrial fibrillation; AFL: atrial flutter; CV: cardiovascular; IS: ischemic stroke; TIA: transient ischemic attack; SE: systemic embolism; eGFR: estimated glomerular filtration rate; DOAC: direct oral anticoagulants; ASA: acetylsalicylic acid; TTR: time in therapeutic range; Missing values for BMI (1,9%) and eGFR (2,0%).
Definition of BMI and eGFR categories as well as risk score categories of CHA2DS2 VASc and HAS-BLED are reported in the Supplementary Material.
TTR was calculated for all patients (n = 791) already on warfarin treatment at admission.